Summit Trail Advisors LLC Grows Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Summit Trail Advisors LLC boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 36.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 7,281 shares of the company’s stock after purchasing an additional 1,927 shares during the quarter. Summit Trail Advisors LLC’s holdings in Moderna were worth $303,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB increased its position in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after buying an additional 389 shares during the last quarter. Blue Trust Inc. increased its position in Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock worth $47,000 after buying an additional 388 shares during the period. EMC Capital Management lifted its stake in Moderna by 311.2% in the fourth quarter. EMC Capital Management now owns 1,250 shares of the company’s stock valued at $52,000 after buying an additional 946 shares during the last quarter. Finally, Larson Financial Group LLC boosted its holdings in shares of Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after acquiring an additional 317 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 2,664 shares of company stock worth $115,210 over the last 90 days. 15.70% of the stock is currently owned by corporate insiders.

Moderna Stock Performance

Shares of MRNA stock opened at $30.53 on Thursday. The stock has a fifty day moving average price of $39.53 and a 200 day moving average price of $56.11. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The stock has a market cap of $11.75 billion, a PE ratio of -5.25 and a beta of 1.59. Moderna, Inc. has a 1 year low of $30.24 and a 1 year high of $170.47.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Piper Sandler restated an “overweight” rating and issued a $69.00 price objective (down from $115.00) on shares of Moderna in a research note on Monday, November 18th. Evercore ISI dropped their price target on Moderna from $60.00 to $50.00 and set an “in-line” rating on the stock in a research report on Monday, January 27th. JPMorgan Chase & Co. decreased their price objective on Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a research report on Tuesday, November 26th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Friday, November 8th. Finally, Barclays cut their price target on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Four equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Moderna presently has a consensus rating of “Hold” and a consensus price target of $66.89.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.